Penpulimab in combination therapy for the first-line treatment of metastatic NPC, has had its marketing application accepted by the NMPA and the FDA. Additionally, the marketing application for its ...
Amid another solid quarter of earnings results, Morningstar analysts have been bumping up their fair value estimates of various stocks. The names with the largest fair value increases were e-commerce ...
CARVYKTI is a B-cell maturation antigen-targeted therapy for treating patients with multiple myeloma ... The CARVYKTI arm showed a 74% reduction in the disease progression or death risk when compared ...
I'm now on my 11th year covering Black Friday deals for Tom's Guide, and I've been covering tech overall since the Palm Pilot was actually a thing. So I know a lot about gadgets — and can tell the ...
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, is pleased to announce that OMAPiX has been certified as the latest member of its Certified Service ...
StudyFirst Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach 21.11.2024 / ...